Estrogens and Progestins

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 855-885

  Turner, Russell T ^a   Rickard, David J ^b   Iwaniec, Urszula T ^a   Spelsberg, Thomas C ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882498269     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00057-4     Document Type: Chapter

References (344)

1. S.F. Ahmed, P. Tucker, et al. (2004) Randomized, crossover comparison study of the short-term effect of oral testosterone undecanoate and intramuscular testosterone depot on linear growth and serum bone alkaline phosphatase. J. Pediatr. Endocrinol. Metab. 17(7), 941-950.
2. A.S. Ali, A.S. Lax, et al. (2006) Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin. Chem. Lab. Med. 44(5), 672-674.
3. P. Ammann, R. Rizzoli, et al. (1997) Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99(7), 1699-1703.
4. B.H. Arjmandi, M.J. Getlinger, et al. (1998) Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am. J. Clin. Nutr. 68(Suppl 6), 1358S-s1363S.
5. V.J. Armstrong, M. Muzylak, et al. (2007) Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. J. Biol. Chem. 282(28), 20715-20727.
6. J. Arts, G.G. Kuiper, et al. (1997) Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138(11), 5067-5070.
7. S.D. Bain, J.P. Lydon, et al. (1997) Mice lacking functional progesterone receptors have no apparent alterations in peak bone mass or histomorphometry. J. Bone Miner. Res. 12(Suppl 1), S461.
8. E. Balk, M. Chung, et al. (2005) Effects of soy on health outcomes. Evid. Rep. Technol. Assess. (Summ.), 126 1-8.
9. E.I. Barengolts, H.F. Gajardo, et al. (1990) Effects of progesterone on postovariectomy bone loss in aged rats. J. Bone Miner. Res. 5(11), 1143-1147.
10. E.I. Barengolts, T. Kouznetsova, et al. (1996) Effects of progesterone on serum levels of IGF-1 and on femur IGF-1 mRNA in ovariectomized rats. J. Bone Miner. Res. 11(10), 1406-1412.
11. E.I. Barengolts, P.V. Lathon, et al. (1995) Progesterone antagonist RU 486 has bone-sparing effects in ovariectomized rats. Bone 17(1), 21-25.
12. W.G. Beamer, L.R. Donahue, et al. (1996) Genetic variability in adult bone density among inbred strains of mice. Bone 18(5), 397-403.
13. C. Belanger, V. Luu-The, et al. (2002) Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm. Metab. Res. 34(11–12), 737-745.
14. T. Bellido, G. Girasole, et al. (1993) Demonstration of estrogen and vitamin D receptors in bone marrow-derived stromal cells: upregulation of the estrogen receptor by 1, 25-dihydroxyvitamin-D3. Endocrinology 133(2), 553-562.
15. H. Ben-Hur, G. Mor, et al. (1993) Localization of estrogen receptors in long bones and vertebrae of human fetuses. Calcif. Tissue Int. 53(2), 91-96.
16. C. Bevan and M. Parker (1999) The role of coactivators in steroid hormone action. Exp. Cell. Res. 253(2), 349-356.
17. L.J. Black, M. Sato, et al. (1994) Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93(1), 63-69.
18. H. Blair, L. Sun, et al. (2007) Balanced regulation of proliferation, growth, differentiation, and degradation in skeletal cells. Ann. N. Y. Acad. Sci. 1116 376-382.
19. M. Bliziotes, J.D. Sibonga, et al. (2006) Periosteal remodeling at the femoral neck in nonhuman primates. J. Bone Miner. Res. 21(7), 1060-1067.
20. P.V. Bodine, R.A. Henderson, et al. (1998) Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression. Endocrinology 139(4), 2048-2057.
21. V. Boonyaratanakornkit, D.D. Strong, et al. (1999) Progesterone stimulation of human insulin-like growth factor-binding protein-5 gene transcription in human osteoblasts is mediated by a CACCC sequence in the proximal promoter. J. Biol. Chem. 274(37), 26431-26438.
22. S. Bord, E. Frith, et al. (2004) Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br. J. Haematol. 126(2), 244-251.
23. B.M. Bowman and S.C. Miller (1996) Elevated progesterone during pseudopregnancy may prevent bone loss associated with low estrogen. J. Bone Miner. Res. 11(1), 15-21.
24. I. Braidman, C. Baris, et al. (2000) Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone 26(5), 423-427.
25. I.P. Braidman, L.K. Davenport, et al. (1995) Preliminary in situ identification of estrogen target cells in bone. J. Bone Miner. Res. 10(1), 74-80.
26. N.A. Breslau, L. Brinkley, et al. (1988) Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J. Clin. Endocrinol. Metab. 66(1), 140-146.
27. K.D. Brubaker and C.V. Gay (1994) Specific binding of estrogen to osteoclast surfaces. Biochem. Biophys. Res. Commun. 200(2), 899-907.
28. K.D. Brubaker and C.V. Gay (1999) Estrogen stimulates protein tyrosine phosphorylation and Src kinase activity in avian osteoclasts. J. Cell Biochem. 76(2), 206-216.
29. R.W. Brueggemeier, B. Su, et al. (2007) Aromatase and COX in breast cancer: Enzyme inhibitors and beyond. J. Steroid Biochem. Mol. Biol. 106(1–5), 16-23.
30. H.U. Bryant, A.L. Glasebrook, et al. (1999) An estrogen receptor basis for raloxifene action in bone. J. Steroid Biochem. Mol. Biol. 69(1–6), 37-44.
31. R. Brynin (2002) Soy and its isoflavones: a review of their effects on bone density. Altern. Med. Rev. 7(4), 317-327.
32. A.M. Brzozowski, A.C. Pike, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652), 753-758.
33. N. Bucay, I. Sarosi, et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12(9), 1260-1268.
34. B. Burguera, L.C. Hofbauer, et al. (2001) Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142(8), 3546-3553.
35. C.C. Burnett and A.H. Reddi (1983) Influence of estrogen and progesterone on matrix-induced endochondral bone formation. Calcif. Tissue Int. 35(4–5), 609-614.
36. E. Canalis and L.G. Raisz (1978) Effect of sex steroids on bone collagen synthesis in vitro. Calcif. Tissue Res. 25(2), 105-110.
37. C. Carani, K. Qin, et al. (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337(2), 91-95.
38. M. Centrella, T.L. McCarthy, et al. (2004) Estren (4-estren-3alpha, 17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol. Endocrinol. 18(5), 1120-1130.
39. D. Chakravarty, R. Srinivasan, et al. (2007) Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int. J. Gynecol. Cancer, 17(4), 905-913.
40. M. Cicek, U.T. Iwaniec, et al. (2007) 2-methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res. 67(21), 10106-10111.
41. S. Clark and D.W. Rowe (1996) Transgenic animals. J.P. Bilezikian (Eds) Principles of Bone Biology San Diego: Academic Press 1491-1502.
42. A.L. Coker, M.M. Crane, et al. (1997) Re: Ethnic differences in estrogen metabolism in healthy women. J. Natl. Cancer Inst. 89(1), 89-90.
43. J.F. Couse and K.S. Korach (1999) Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev. 20(3), 358-417.
44. G.B. Cutler Jr. (1997) The role of estrogen in bone growth and maturation during childhood and adolescence. J. Steroid Biochem. Mol. Biol. 61(3–6), 141-144.
45. E. Damien, J.S. Price, et al. (1998) The estrogen receptor's involvement in osteoblasts’ adaptive response to mechanical strain. J. Bone Miner. Res. 13(8), 1275-1282.
46. M.E. de Gooyer, G.H. Deckers, et al. (2003) Receptor profiling and endocrine interactions of tibolone. Steroids 68(1), 21-30.
47. M.E. de Gooyer, G.T. Kleyn, et al. (2001) Tibolone: A compound with tissue-specific inhibitory effects on sulfatase. Mol. Cell Endocrinol. 183(1–2), 55-62.
48. M.J. De Souza, B.E. Miller, et al. (1997) Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J. Clin. Endocrinol. Metab. 82(9), 2867-2876.
49. A. de Wilde, C. Heberden, et al. (2006) Signaling networks from Gbeta1 subunit to transcription factors and actin remodeling via a membrane-located ERbeta-related protein in the rapid action of daidzein in osteoblasts. J. Cell Physiol. 209(3), 786-801.
50. P.D. Delmas, N.H. Bjarnason, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337(23), 1641-1647.
51. D.W. Dempster, R. Birchman, et al. (1995) Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone 16(1), 157-161.
52. W. Dietrich, A. Haitel, et al. (2006) Estrogen receptor-beta is the predominant estrogen receptor subtype in normal human synovia. J. Soc. Gynecol. Investig. 13(7), 512-517.
53. C. Dimitrakakis, L. Gosselink, et al. (2004) Phytoestrogen supplementation: A case report of male breast cancer. Eur. J. Cancer Prev. 13(6), 481-484.
54. C.R. Draper, M.J. Edel, et al. (1997) Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats. J. Nutr. 127(9), 1795-1799.
55. M.W. Draper, D.E. Flowers, et al. (1996) A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11(6), 835-842.
56. L. Dunkel and S. Wickman (2002) Novel treatment of delayed male puberty with aromatase inhibitors. Horm. Res. 57(Suppl 2), 44-52.
57. J. Eden (2005) The need for tissue selective menopausal agents. Gynecol. Endocrinol. 21(Suppl 1), 22-27.
58. A.G. Ederveen and H.J. Kloosterboer (1999) Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. J. Bone Miner. Res. 14(11), 1963-1970.
59. H. Endoh, H. Sasaki, et al. (1997) Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun. 235(1), 99-102.
60. A. Enjuanes, N. Garcia-Giralt, et al. (2005) Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. Eur. J. Endocrinol. 153(6), 981-988.
61. E.F. Eriksen, D.S. Colvard, et al. (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241(4861), 84-86.
62. M. Ernst, J.K. Heath, et al. (1989) Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125(2), 825-833.
63. M.C. Etienne, J.L. Fischel, et al. (1990) Steroid receptors in human osteoblast-like cells. Eur. J. Cancer. 26(7), 807-810.
64. G. Evans, H.U. Bryant, et al. (1994) The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134(5), 2283-2288.
65. G.L. Evans, H.U. Bryant, et al. (1996) Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137(10), 4139-4144.
66. P. Fanti, M.C. Monier-Faugere, et al. (1998) The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos. Int. 8(3), 274-281.
67. K.L. Fink, E.D. Wieben, et al. (1988) Rapid regulation of c-myc proto-oncogene expression by progesterone in the avian oviduct. Proc. Natl. Acad. Sci. U. S. A. 85(6), 1796-1800.
68. G. Fiorelli, F. Gori, et al. (1996) Membrane binding sites and nongenomic effects of estrogen in cultured human pre-osteoclastic cells. J. Steroid Biochem. Mol. Biol. 59(2), 233-240.
69. G. Fiorelli, F. Gori, et al. (1995) Functional estrogen receptors in a human preosteoclastic cell line. Proc. Natl. Acad. Sci. U. S. A. 92(7), 2672-2676.
70. G. Fiorelli, V. Martineti, et al. (1997) Heterogeneity of binding sites and bioeffects of raloxifene on the human leukemic cell line FLG 29.1. Biochem Biophys. Res. Commun. 240(3), 573-579.
71. J. Fishman and C. Martucci (1980) Biological properties of 16 alpha-hydroxyestrone: Implications in estrogen physiology and pathophysiology. J. J. Clin. Endocrinol. Metab. 51(3), 611-615.
72. J. Fishman, J. Schneider, et al. (1984) Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J. J. Steroid Biochem. 20(4B), 1077-1081.
73. L.A. Fitzpatrick, E. Buzas, et al. (2003) Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc. Natl. Acad. Sci. U. S. A. 100(10), 6027-6032.
74. A. Forlino, R. Piazza, et al. (2005) A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: Morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum. Mol. Genet. 14(6), 859-871.
75. T. Fotsis, Y. Zhang, et al. (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368(6468), 237-239.
76. B. Fournier, S. Haring, et al. (1996) Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J. Endocrinol. 150(2), 275-285.
77. D.W. Frayer and M.H. Wolpoff (1985) Sexual dimorphism. Ann. Rev. Anthropol. 14 429-473.
78. H.M. Frost (1987) Bone mass and the mechanostat: A proposal. Anat. Rec. 219(1), 1-9.
79. T. Fujimaki, T. Kurabayashi, et al. (1995) Effects of progesterone on the metabolism of cancellous bone in young oophorectomized rats. J. Obstet. Gynaecol. 21(1), 31-36.
80. R. Galien, H.F. Evans, et al. (1996) Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens. Mol. Endocrinol. 10(6), 713-722.
81. J.C. Gallagher, W.T. Kable, et al. (1991) Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. Am. J. Med. 90(2), 171-178.
82. C.V. Gay, N.L. Kief, et al. (1993) Effect of estrogen on acidification in osteoclasts. Biochem. Biophys. Res. Commun. 192(3), 1251-1259.
83. P.H. Giangrande and D.P. McDonnell (1999) The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Recent Prog. Horm. Res. 54 291-313. discussion 313–314
84. G. Girasole, R.L. Jilka, et al. (1992) 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89(3), 883-891.
85. A. Gohel, M.B. McCarthy, et al. (1999) Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 140(11), 5339-5347.
86. Y. Gong, R.B. Slee, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513-523.
87. A. Goulding and L. Fisher (1991) 17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin. Bone Miner. 13(1), 47-53.
88. A. Grey, T. Cundy, et al. (1996) Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin. Endocrinol. (Oxf.), 44(3), 293-296.
89. B. Grosse, M. Kachkache, et al. (2000) Membrane signalling and progesterone in female and male osteoblasts. I. Involvement of intracellular Ca(2+), inositol trisphosphate, and diacylglycerol, but not cAMP. J. Cell Biochem. 79(2), 334-345.
90. J.A. Gustafsson (1998) Therapeutic potential of selective estrogen receptor modulators. Curr. Opin. Chem. Biol. 2(4), 508-511.
91. J.M. Hall and D.P. McDonnell (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140(12), 5566-5578.
92. J. Hallgren and M.F. Gurish (2007) Pathways of murine mast cell development and trafficking: Tracking the roots and routes of the mast cell. Immunol. Rev. 217 8-18.
93. M.W. Hamrick (2004) Leptin, bone mass, and the thrifty phenotype. J. Bone Miner. Res. 19(10), 1607-1611.
94. M.W. Hamrick, C. Pennington, et al. (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34(3), 376-383.
95. K.O. Han, J.T. Choi, et al. (2005) The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with estrogen responsiveness on bone. Clin. Endocrinol. (Oxf.) 62(3), 349-353.
96. S.A. Harris, R.J. Enger, et al. (1995) Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J. Bone Miner. Res. 10(2), 178-186.
97. S.A. Harris, K.R. Tau, et al. (1995) Estrogen response in the hFOB 1.19 human fetal osteoblastic cell line stably transfected with the human estrogen receptor gene. J. Cell Biochem. 59(2), 193-201.
98. E. Harrison, A. Adjei, et al. (1998) The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. J. Nutr. Sci. Vitaminol. (Tokyo), 44(2), 257-268.
99. J.R. Hawse, M. Subramaniam, et al. (2008) Estrogen-TGFbeta cross-talk in bone and other cell types: Role of TIEG, Runx2, and other transcription factors. J. Cell Biochem. 103 383-392.
100. R.P. Heaney, R. Carey, et al. (2005) Roles of vitamin D, n-3 polyunsaturated fatty acid, and soy isoflavones in bone health. J. Am. Diet Assoc. 105(11), 1700-1702.
101. C. Heberden, F. Reine, et al. (2006) Detection of a raft-located estrogen receptor-like protein distinct from ER alpha. Int. J. Chem. Biochem. Cell Biol. 38(3), 376-391.
102. S.C. Hewitt, J. Collins, et al. (2006) Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus. Endocrinology 147(5), 2203-2214.
103. E.L. Hill, R. Turner, et al. (1991) Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 44(3), 747-755.
104. L.C. Hofbauer, S. Khosla, et al. (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140(9), 4367-4370.
105. J.A. Hoyland, A.P. Mee, et al. (1997) Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone 20(2), 87-92.
106. D.E. Hughes, A. Dai, et al. (1996) Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 2(10), 1132-1136.
107. C.D. Humfrey (1998) Phytoestrogens and human health effects: Weighing up the current evidence. Nat. Toxins 6(2), 51-59.
108. A. Ikegami, S. Inoue, et al. (1994) Cell cycle-dependent expression of estrogen receptor and effect of estrogen on proliferation of synchronized human osteoblast-like osteosarcoma cells. Endocrinology 135(2), 782-789.
109. A. Irie, M. Takami, et al. (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41(2), 165-174.
110. Y. Ishida and J.N. Heersche (1997) Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone 20(1), 17-25.
111. Y. Ishida and J.N. Heersche (1999) Progesterone- and dexamethasone-dependent osteoprogenitors in bone cell populations derived from rat vertebrae are different and distinct. Endocrinology 140(7), 3210-3218.
112. Y. Ishimi, C. Miyaura, et al. (1999) Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology 140(4), 1893-1900.
113. I. Iwamoto, T. Fujino, et al. (2004) The leptin receptor in human osteoblasts and the direct effect of leptin on bone metabolism. Gynecol. Endocrinol. 19(2), 97-104.
114. U.T. Iwaniec, S. Boghossian, et al. (2007) Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides 28(5), 1012-1019.
115. U.T. Iwaniec and R.T. Turner (2008) Animal models for osteoporosis. R. Marcus, D. Feldman, Nelson, C.J. Rosen (Eds) Osteoporosis San Diego: Academic Press 985-1009.
116. U.T. Iwaniec, D. Yuan, et al. (2006) Strain-dependent variations in the response of cancellous bone to ovariectomy in mice. J. Bone Miner. Res. 21(7), 1068-1074.
117. M.J. Jayo, D.S. Weaver, et al. (1990) Effects on bone of surgical menopause and estrogen therapy with or without progesterone replacement in cynomolgus monkeys. Am. J. Obstet. Gynecol. 163(2), 614-618.
118. C.P. Jerome, D.B. Kimmel, et al. (1986) Effects of ovariectomy on iliac trabecular bone in baboons (Papio anubis). Calcif. Tissue Int. 39(3), 206-208.
119. R.L. Jilka, G. Hangoc, et al. (1992) Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257(5066), 88-91.
120. R.L. Jilka, K. Takahashi, et al. (1998) Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101(9), 1942-1950.
121. D.N. Kalu, C.C. Liu, et al. (1989) The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 124(1), 7-16.
122. D.N. Kalu, E. Salerno, et al. (1991) A comparative study of the actions of tamoxifen, estrogen, and progesterone in the ovariectomized rat. Bone Miner. 15(2), 109-123.
123. T. Kameda, H. Mano, et al. (1997) Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186(4), 489-495.
124. M. Kanatani, T. Sugimoto, et al. (1998) Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J. Bone Miner. Res. 13(5), 854-862.
125. K.K. Karambolova, G.R. Snow, et al. (1987) Effects of continuous 17 beta-estradiol administration on the periosteal and corticoendosteal envelope activity in spayed beagles. Calcif. Tissue Int. 40(1), 12-15.
126. G. Karsenty (2001) Leptin controls bone formation through a hypothalamic relay. Recent Prog. Horm. Res. 56 401-415.
127. M. Kassem, R. Okazaki, et al. (1996) Potential mechanism of estrogen-mediated decrease in bone formation: Estrogen increases production of inhibitory insulin-like growth factor-binding protein-4. Proc. Assoc. Am. Physicians 108(2), 155-164.
128. P. Kastner, A. Krust, et al. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9(5), 1603-1614.
129. T. Kawai, T. Matsuyama, et al. (2006) B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 169(3), 987-998.
130. H.Z. Ke, T.A. Brown, et al. (2002) The role of estrogen receptor-beta, in the early age-related bone gain and later age-related bone loss in female mice. J. Musculoskelet. Neuronal Interact. 2(5), 479-488.
131. P.E. Keeting, R.E. Scott, et al. (1991) Lack of a direct effect of estrogen on proliferation and differentiation of normal human osteoblast-like cells. J. Bone Miner. Res. 6(3), 297-304.
132. A.M. Kennedy, K.L. Shogren, et al. (2005) 17beta-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology 146(1), 201-207.
133. S. Khosla, H.M. Arrighi, et al. (2002) Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 13(5), 394-399.
134. L.S. Kidder, I.U. Schmidt, et al. (1997) Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats. Calcif. Tissue Int. 61(4), 327-335.
135. R.B. Kimble, S. Bain, et al. (1997) The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J. Bone Miner. Res. 12(6), 935-941.
136. R.B. Kimble, A.B. Matayoshi, et al. (1995) Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136(7), 3054-3061.
137. R.B. Kimble, S. Srivastava, et al. (1996) Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271(46), 28890-28897.
138. H.J. Kloosterboer (2004) Tissue-selectivity: The mechanism of action of tibolone. Maturitas 48(Suppl 1), S30-s40.
139. B.S. Komm, C.M. Terpening, et al. (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241(4861), 81-84.
140. S.A. Kontulainen, H.M. Macdonald, et al. (2006) Change in cortical bone density and its distribution differs between boys and girls during puberty. J. Clin. Endocrinol. Metab. 91(7), 2555-2561.
141. K.S. Korach, M. Taki, et al. (1997) The effects of estrogen receptor gene distribution on bone. R. Paoletti (Eds) Women's Health and Menopause Amsterdam: Kluwer Academic and Fondazione Giananni Lorenzini 69-73.
142. S. Kousteni, T. Bellido, et al. (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104(5), 719-730.
143. S. Kousteni, J.R. Chen, et al. (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298(5594), 843-846.
144. W.L. Kraus, K.E. Weis, et al. (1995) Inhibitory cross-talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol. Cell Biol. 15(4), 1847-1857.
145. M. Kremer, J. Judd, et al. (1995) Estrogen modulation of osteoclast lysosomal enzyme secretion. J. Cell Biochem. 57(2), 271-279.
146. V. Krishnan, H.A. Bullock, et al. (2005) The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol. Pharmacol. 67(3), 744-748.
147. V. Krishnan, X. Wang, et al. (1994) Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 269(22), 15912-15917.
148. G.G. Kuiper, B. Carlsson, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3), 863-870.
149. G.G. Kuiper, E. Enmark, et al. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93(12), 5925-5930.
150. G.G. Kuiper and J.A. Gustafsson (1997) The novel estrogen receptor-beta subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410(1), 87-90.
151. G.G. Kuiper, J.G. Lemmen, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139(10), 4252-4263.
152. H. Kuivaniemi, G. Tromp, et al. (1991) Mutations in collagen genes: Causes of rare and some common diseases in humans. FASEB J. 5(7), 2052-2060.
153. D. Kupfer and W.H. Bulger (1976) Interactions of chlorinated hydrocarbons with steroid hormones. Fed. Proc. 35(14), 2603-2608.
154. V. Kusec, A.S. Virdi, et al. (1998) Localization of estrogen receptor-alpha in human and rabbit skeletal tissues. J. Clin. Endocrinol. Metab. 83(7), 2421-2428.
155. J.P. Landers and T.C. Spelsberg (1992) New concepts in steroid hormone action: Transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit. Rev. Eukaryot. Gene Expr. 2(1), 19-63.
156. K.H. Lau, S. Kapur, et al. (2006) Upregulation of the Wnt, estrogen receptor, insulin-like growth factor-I, and bone morphogenetic protein pathways in C57BL/6J osteoblasts as opposed to C3H/HeJ osteoblasts in part contributes to the differential anabolic response to fluid shear. J. Biol. Chem. 281(14), 9576-9588.
157. F. Lazner, M. Gowen, et al. (1999) Osteopetrosis and osteoporosis: Two sides of the same coin. Hum. Mol. Genet. 8(10), 1839-1846.
158. V. Le Mellay, F. Lasmoles, et al. (1999) Galpha(q/11) and gbetagamma proteins and membrane signaling of calcitriol and estradiol. J. Cell Biochem. 75(1), 138-146.
159. K.C. Lee, H. Jessop, et al. (2004) The adaptive response of bone to mechanical loading in female transgenic mice is deficient in the absence of oestrogen receptor-alpha and -beta. J. Endocrinol. 182(2), 193-201.
160. D. LeRoith and S. Yakar (2007) Mechanisms of disease: Metabolic effects of growth hormone and insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 3(3), 302-310.
161. Y.K. Leung, P. Mak, et al. (2006) Estrogen receptor (ER)-beta isoforms: A key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 103(35), 13162-13167.
162. X. Li, M. Takahashi, et al. (1998) The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J. Bone Miner. Res. 13(6), 1005-1010.
163. M. Lieberherr, B. Grosse, et al. (1993) Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional nonnuclear receptors. J. Bone Miner. Res. 8(11), 1365-1376.
164. S.K. Lim, Y.J. Won, et al. (1999) A PCR analysis of ERalpha and ERbeta mRNA abundance in rats and the effect of ovariectomy. J. Bone Miner. Res. 14(7), 1189-1196.
165. S.K. Lim, Y.J. Won, et al. (1997) Altered hydroxylation of estrogen in patients with postmenopausal osteopenia. J. Clin. Endocrinol. Metab. 82(4), 1001-1006.
166. S.C. Lin, T. Yamate, et al. (1997) Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J. Clin. Invest. 100(8), 1980-1990.
167. Y. Lin, L.J. Liu, et al. (2004) Effect of raloxifene and its interaction with human PTH on bone formation. J. Endocrinol. Invest. 27(5), 416-423.
168. R. Lindsay, J.M. Aitken, et al. (1978) The effect of ovarian sex steroids on bone mineral status in the oophorectomized rat and in the human. Postgrad. Med. J. 54(Suppl 2), 50-58.
169. Z. Liu, E. Graff, et al. (2000) Effect of raloxifene-analog (LY 117018-Hcl) on the bone marrow of ovariectomized mice. J. Cell Biochem. 76(3), 509-517.
170. R.A. Lobo, W. McCormick, et al. (1984) Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet. Gynecol. 63(1), 1-5.
171. D.M. Lonard and C.L. Smith (2002) Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67(1), 15-24.
172. C. Longcope, L. Hoberg, et al. (1989) The effect of ovariectomy on spine bone mineral density in rhesus monkeys. Bone 10(5), 341-344.
173. M. Lorentzon, C. Swanson, et al. (2005) Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J. Bone Miner. Res. 20(8), 1334-1341.
174. J.A. Lorenzo, A. Naprta, et al. (1998) Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139(6), 3022-3025.
175. X.H. Luo, L.J. Guo, et al. (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J. Bone Miner. Res. 21(10), 1648-1656.
176. J.P. Lydon, F.J. DeMayo, et al. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9(18), 2266-2278.
177. H. Macdonald, S. Kontulainen, et al. (2006) Bone strength and its determinants in pre- and early pubertal boys and girls. Bone 39(3), 598-608.
178. P. MacNamara, C. O'Shaughnessy, et al. (1995) Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif. Tissue Int. 57(6), 436-441.
179. P. MacNamara, J. Skillington, et al. (1998) Studies on progesterone receptor expression in human osteoblast cells. Biochem. Soc. Trans. 26(1), S1.
180. R.J. Majeska, J.T. Ryaby, et al. (1994) Direct modulation of osteoblastic activity with estrogen. J. Bone Joint Surg Am. 76(5), 713-721.
181. F.P. Mandel, B.J. Davidson, et al. (1982) Effects of progestins on bone metabolism in postmenopausal women. J. Reprod. Med. 27(Suppl 8), 511-514.
182. D.R. Mann, K.G. Gould, et al. (1990) A potential primate model for bone loss resulting from medical oophorectomy or menopause. J. Clin. Endocrinol. Metab. 71(1), 105-110.
183. H. Mano, T. Yuasa, et al. (1996) Mammalian mature osteoclasts as estrogen target cells. Biochem. Biophys. Res. Commun. 223(3), 637-642.
184. S.C. Manolagas (1999) Cell number versus cell vigor–what really matters to a regenerating skeleton? Endocrinology 140(10), 4377-4381.
185. D.L. Manzi, C.C. Pilbeam, et al. (1994) The anabolic effects of progesterone on fetal rat calvaria in tissue culture. J. Soc Gynecol. Investig. 1(4), 302-309.
186. A. Maran, K. Shogren, et al. (2006) Effects of stable transfection of human fetal osteoblast cells with estrogen receptor-alpha on regulation of gene expression by tibolone. Bone 39(3), 523-529.
187. A. Maran, M. Zhang, et al. (2002) 2-methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 30(2), 393-398.
188. R.B. Martin, R.L. Butcher, et al. (1987) Effects of ovariectomy in beagle dogs. Bone 8(1), 23-31.
189. C.P. Martucci and J. Fishman (1993) P450 enzymes of estrogen metabolism. Pharmacol. Ther. 57(2–3), 237-257.
190. A. Masuyama, Y. Ouchi, et al. (1992) Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblastic cells and effect of steroid hormones on cell proliferation. Calcif. Tissue Int. 51(5), 376-381.
191. E. Mathieu and J. Merregaert (1994) Characterization of the stromal osteogenic cell line MN7: mRNA steady-state level of selected osteogenic markers depends on cell density and is influenced by 17 beta-estradiol. J. Bone Miner. Res. 9(2), 183-192.
192. N.J. McKenna, R.B. Lanz, et al. (1999) Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 20(3), 321-344.
193. S.G. McNeeley Jr., J.S. Schinfeld, et al. (1991) Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women. Int. J. Gynaecol. Obstet. 34(3), 253-256.
194. U.J. Meinhardt and K.K. Ho (2006) Modulation of growth hormone action by sex steroids. Clin. Endocrinol. (Oxf.) 65(4), 413-422.
195. C. Mendez-Davila, C. Garcia-Moreno, et al. (2004) Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J. Endocrinol. Invest. 27(10), 904-912.
196. A. Migliaccio, M. Di Domenico, et al. (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15(6), 1292-1300.
197. Y. Miki, T. Suzuki, et al. (2007) Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone 40(4), 876-887.
198. S.C. Miller and B.M. Bowman (2007) Rapid inactivation and apoptosis of osteoclasts in the maternal skeleton during the bone remodeling reversal at the end of lactation. Anat. Rec. (Hoboken), 290(1), 65-73.
199. C. Miyaura, K. Kusano, et al. (1995) Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10(9), 1365-1373.
200. U.I. Modder, A. Sanyal, et al. (2004) Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology 145(2), 913-921.
201. D. Modrowski, L. Miravet, et al. (1993) Increased proliferation of osteoblast precursor cells in estrogen-deficient rats. Am. J. Physiol. 264(2 Pt 1), E190-eE196.
202. D.G. Monroe, B.J. Getz, et al. (2003) Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J. Cell Biochem. 90(2), 315-326.
203. D.G. Monroe, S.A. Johnsen, et al. (2003) Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. J. Endocrinol. 176(3), 349-357.
204. D.G. Monroe, F.J. Secreto, et al. (2006) Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements. J. Biol. Chem. 281(39), 28596-28604.
205. D.G. Monroe, F.J. Secreto, et al. (2005) Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol. 19(6), 1555-1568.
206. R.L. Moss, Q. Gu, et al. (1997) Estrogen: Nontranscriptional signaling pathway. Recent Prog. Horm. Res. 52 33-68. discussion 68–69
207. S. Mosselman, J. Polman, et al. (1996) ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett. 392(1), 49-53.
208. B. Mulac-Jericevic, R.A. Mullinax, et al. (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289(5485), 1751-1754.
209. L.J. Murphy, L.C. Murphy, et al. (1987) Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 120(5), 1882-1888.
210. M. Nakai, L. Cook, et al. (2005) Dietary soy protein and isoflavones have no significant effect on bone and a potentially negative effect on the uterus of sexually mature intact Sprague-Dawley female rats. Menopause 12(3), 291-298.
211. T. Nakamura, Y. Imai, et al. (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130(5), 811-823.
212. R.S. Newfield, I.M. Spitz, et al. (2001) Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. (Oxf.), 54(3), 399-404.
213. L.O. Nilsson, A. Boman, et al. (1999) Demonstration of estrogen receptor-beta immunoreactivity in human growth plate cartilage. J. Clin. Endocrinol. Metab. 84(1), 370-373.
214. O. Nilsson, D. Chrysis, et al. (2003) Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages. J. Endocrinol. 177(2), 319-326.
215. K. North and J. Golding (2000) A maternal vegetarian diet in pregnancy is associated with hypospadias. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. BJU Int. 85(1), 107-113.
216. Y. Onoe, C. Miyaura, et al. (1997) Expression of estrogen receptor beta in rat bone. Endocrinology 138(10), 4509-4512.
217. R.O. Oreffo, V. Kusec, et al. (1999) Human bone marrow osteoprogenitors express estrogen receptor-alpha and bone morphogenetic proteins 2 and 4mRNA during osteoblastic differentiation. J. Cell Biochem. 75(3), 382-392.
218. M.J. Oursler (1998) Estrogen regulation of gene expression in osteoblasts and osteoclasts. Crit. Rev. Eukaryot. Gene Expr. 8(2), 125-140.
219. M.J. Oursler, P. Osdoby, et al. (1991) Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. U. S. A. 88(15), 6613-6617.
220. M.J. Oursler, L. Pederson, et al. (1994) Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc. Natl. Acad. Sci. U. S. A. 91(12), 5227-5231.
221. M.J. Oursler, L. Pederson, et al. (1993) Estrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology 132(3), 1373-1380.
222. R. Pacifici, C. Brown, et al. (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U. S. A. 88(12), 5134-5138.
223. R. Pacifici, L. Rifas, et al. (1989) Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. U. S. A. 86(7), 2398-2402.
224. K. Paech, P. Webb, et al. (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277(5331), 1508-1510.
225. L.A. Paige, D.J. Christensen, et al. (1999) Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U. S. A. 96(7), 3999-4004.
226. D. Pascoe and M.J. Oursler (2001) The Src signaling pathway regulates osteoclast lysosomal enzyme secretion and is rapidly modulated by estrogen. J. Bone Miner. Res. 16(6), 1028-1036.
227. G. Passeri, G. Girasole, et al. (1993) Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 133(2), 822-828.
228. L. Pederson, M. Kremer, et al. (1997) Evidence of a correlation of estrogen receptor level and avian osteoclast estrogen responsiveness. J. Bone Miner. Res. 12(5), 742-752.
229. PEPI (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 276(17), 1389-1396.
230. A.M. Pino, J.M. Rodriguez, et al. (2006) Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J. Endocrinol. 191(3), 715-725.
231. V. Poli, R. Balena, et al. (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13(5), 1189-1196.
232. S.M. Potter, J.A. Baum, et al. (1998) Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 68(Suppl 6), 1375S-s1379S.
233. J.C. Prior, Y.M. Vigna, et al. (1994) Cyclic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances. Am. J. Med. 96(6), 521-530.
234. J.C. Prior, Y.M. Vigna, et al. (1990) Spinal bone loss and ovulatory disturbances. N. Engl. J. Med. 323(18), 1221-1227.
235. J.C. Prior, Y.M. Vigna, et al. (1997) Premenopausal ovariectomy-related bone loss: A randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J. Bone Miner. Res. 12(11), 1851-1863.
236. Q. Qu, P.L. Harkonen, et al. (1999) Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J. Cell Biochem. 73(4), 500-507.
237. A.C. Ramalho, P. Couttet, et al. (2002) Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur. Cytokine Netw. 13(1), 39-45.
238. M. Rauner, W. Sipos, et al. (2007) Osteoimmunology. Int. Arch. Allergy Immunol. 143(1), 31-48.
239. J.E. Reed, L.W. Woo, et al. (2004) 2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 317(1), 169-175.
240. T.C. Register, M.J. Jayo, et al. (2003) Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. J. Clin. Endocrinol. Metab. 88(9), 4362-4370.
241. A. Revelli, M. Massobrio, et al. (1998) Nongenomic actions of steroid hormones in reproductive tissues. Endocr. Rev. 19(1), 3-17.
242. D. Rickard, G. Russell, et al. (1992) Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos. Int. 2(2), 94-102.
243. D.J. Rickard, M. Gowen, et al. (1993) Proliferative responses to estradiol, IL-1 alpha and TGF beta by cells expressing alkaline phosphatase in human osteoblast-like cell cultures. Calcif. Tissue Int. 52(3), 227-233.
244. D.J. Rickard, I. Kazhdan, et al. (1995) Importance of 1, 25-dihydroxyvitamin D3 and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. Bone 16(6), 671-678.
245. D.J. Rickard, K.M. Waters, et al. (1999) Bone histomorphometric analysis of progesterone receptor deficient mice. J. Bone Miner. Res. 14(Suppl 1), S297.
246. D.J. Rickard, U.J. Iwaniec, et al. (2008) Bone growth and turnover in progesterone receptor knockout mice. Endocrinology 149(5), 2383-2390.
247. L. Rifas, J.S. Kenney, et al. (1995) Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: Evidence that induction by interleukin-1 and tumor necrosis factor-alpha is not regulated by ovarian steroids. Endocrinology 136(9), 4056-4067.
248. B.J. Riis, K. Overgaard, et al. (1995) Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos. Int. 5(4), 276-280.
249. A.K. Rishi, Z.M. Shao, et al. (1995) Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Res. 55(21), 4999-5006.
250. J.A. Robinson, S.A. Harris, et al. (1997) Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138(7), 2919-2927.
251. J.A. Robinson, K.M. Waters, et al. (2000) Direct action of naturally occurring estrogen metabolites on human osteoblastic cells. J. Bone Miner. Res. 15(3), 499-506.
252. D. Robyr, A.P. Wolffe, et al. (2000) Nuclear hormone receptor coregulators in action: Diversity for shared tasks. Mol. Endocrinol. 14(3), 329-347.
253. F.M. Sacks, A. Lichtenstein, et al. (2006) Soy protein, isoflavones, and cardiovascular health: An American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113(7), 1034-1044.
254. L. Salvatori, L. Ravenna, et al. (2000) Identification of an estrogen-mediated deoxyribonucleic acid-binding independent transactivation pathway on the epidermal growth factor receptor gene promoter. Endocrinology 141(6), 2266-2274.
255. B. Saville, M. Wormke, et al. (2000) Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275(8), 5379-5387.
256. L.K. Saxon, A.G. Robling, et al. (2007) The skeletal responsiveness to mechanical loading is enhanced in mice with a null mutation in estrogen receptor-beta. Am. J. Physiol. Endocrinol. Metab. 293(2), E484-eE491.
257. B.A. Scheven, C.A. Damen, et al. (1992) Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem. Biophys. Res. Commun. 186(1), 54-60.
258. I.U. Schmidt, G.K. Wakley, et al. (2000) Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif. Tissue Int. 67(1), 47-52.
259. J. Schneider, M.M. Huh, et al. (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem. 259(8), 4840-4845.
260. A. Scutt, U. Kollenkirchen, et al. (1996) Effect of age and ovariectomy on fibroblastic colony-forming unit numbers in rat bone marrow. Calcif. Tissue Int. 59(4), 309-310.
261. F.J. Secreto, D.G. Monroe, et al. (2007) Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J. Cell Biochem. 101(5), 1125-1147.
262. N.K. Shevde, A.C. Bendixen, et al. (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U. S. A. 97(14), 7829-7834.
263. K.L. Shogren, R.T. Turner, et al. (2007) Double-stranded RNA-dependent protein kinase is involved in 2-methoxyestradiol-mediated cell death of osteosarcoma cells. J. Bone Miner. Res. 22(1), 29-36.
264. J.D. Sibonga, H. Dobnig, et al. (1998) Effect of the high-affinity estrogen receptor ligand ICI182, 780 on the rat tibia. Endocrinology 139(9), 3736-3742.
265. J.D. Sibonga, S. Lotinun, et al. (2003) Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144(3), 785-792.
266. J.D. Sibonga, U. Sommer, et al. (2002) Evidence that 2-methoxyestradiol suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes. J. Cancer Res. Clin. Oncol. 128(9), 477-483.
267. J.D. Sibonga, M. Zhang, et al. (2000) Restoration of bone mass in the severely osteopenic senescent rat. J. Gerontol. A. Biol. Sci. Med. Sci. 55(2), B71-bb78. discussion B79–84
268. G. Sigurdsson, T. Aspelund, et al. (2006) Increasing sex difference in bone strength in old age: The Age, Gene/Environment Susceptibility-Reykjavik study (AGES-REYKJAVIK). Bone 39(3), 644-651.
269. T. Simoncini, A. Hafezi-Moghadam, et al. (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407(6803), 538-541.
270. W.S. Simonet, D.L. Lacey, et al. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89(2), 309-319.
271. N.A. Sims, P. Clement-Lacroix, et al. (2003) A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J. Clin. Invest. 111(9), 1319-1327.
272. N.A. Sims, S. Dupont, et al. (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30(1), 18-25.
273. M.C. Slootweg, A.G. Ederveen, et al. (1992) Oestrogen and progestogen synergistically stimulate human and rat osteoblast proliferation. J. Endocrinol. 133(2), R5-r8.
274. C.L. Smith, Z. Nawaz, et al. (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11(6), 657-666.
275. E.P. Smith, J. Boyd, et al. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331(16), 1056-1061.
276. G.R. Snow and C. Anderson (1985) The effects of continuous progestereone treatment on cortical bone remodeling activity in beagles. Calcif. Tissue Int. 37 282-286.
277. M.G. Sorensen, K. Henriksen, et al. (2006) Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol. 25(8), 475-483.
278. T. Spelsberg, M. Subramaniam, et al. (1992) Nuclear proto-oncogenes as regulatory genes and as marker genses for steroid action in all target tissues. S. Kahn, G. Stancel (Eds) Proto-oncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation Boca Raton, FL: CRC Press
279. T.C. Spelsberg, M. Subramaniam, et al. (1999) The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13(6), 819-828.
280. M.S. Springer, W.J. Murphy, et al. (2003) Placental mammal diversification and the Cretaceous-Tertiary boundary. Proc. Natl. Acad. Sci. U. S. A. 100(3), 1056-1061.
281. S. Srivastava, G. Toraldo, et al. (2001) Estrogen decreases osteoclast formation by downregulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276(12), 8836-8840.
282. B. Stein and M.X. Yang (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell Biol. 15(9), 4971-4979.
283. C.M. Steppan, D.T. Crawford, et al. (2000) Leptin is a potent stimulator of bone growth in ob/ob mice. Regul. Pept. 92(1–3), 73-78.
284. T. Sunyer, J. Lewis, et al. (1999) Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Invest. 103(10), 1409-1418.
285. G.E. Swaneck and J. Fishman (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: Characterization and intranuclear localization. Proc. Natl. Acad. Sci. U. S. A. 85(21), 7831-7835.
286. P. Szulc, E. Seeman, et al. (2006) Bone fragility: Failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J. Bone Miner. Res. 21(12), 1856-1863.
287. H. Takai, M. Kanematsu, et al. (1998) Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273(42), 27091-27096.
288. K.R. Tau, T.E. Hefferan, et al. (1998) Estrogen regulation of a transforming growth factor-beta inducible early gene that inhibits deoxyribonucleic acid synthesis in human osteoblasts. Endocrinology 139(3), 1346-1353.
289. L. Thommesen, A.K. Stunes, et al. (2006) Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J. Cell Biochem. 99(3), 824-834.
290. C.J. Timmer and J.A. Huisman (2002) Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5mg in healthy postmenopausal women. Pharmacotherapy 22(3), 310-315.
291. A. Tomkinson, E.F. Gevers, et al. (1998) The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 13(8), 1243-1250.
292. A. Tomkinson, J. Reeve, et al. (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82(9), 3128-3135.
293. F.A. Tremollieres, D.D. Strong, et al. (1992) Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol. (Copenh.), 126(4), 329-337.
294. M.J. Tsai and B.W. O'Malley (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 451-486.
295. C.H. Turner, M. Sato, et al. (1994) Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135(5), 2001-2005.
296. R.T. Turner (1994) Cancellous bone turnover in growing rats: Time-dependent changes in association between calcein label and osteoblasts. J. Bone Miner. Res. 9(9), 1419-1424.
297. R.T. Turner (1999) Mice, estrogen, and postmenopausal osteoporosis. J. Bone Miner. Res. 14(2), 187-191.
298. R.T. Turner, P. Backup, et al. (1992) Mechanism of action of estrogen on intramembranous bone formation: regulation of osteoblast differentiation and activity. Endocrinology 131(2), 883-889.
299. R.T. Turner, D.S. Colvard, et al. (1990) Estrogen inhibition of periosteal bone formation in rat long bones: Downregulation of gene expression for bone matrix proteins. Endocrinology 127(3), 1346-1351.
300. R.T. Turner and L.P. Eliel (1978) o, p′-DDT as an estrogen: An evaluation of its ability to compete with 3H-estradiol for nuclear estrogen receptor sites in the quail oviduct. Bull. Environ. Contam. Toxicol. 19(2), 139-142.
301. R.T. Turner and G.L. Evans (2000) 2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif. Tissue Int. 66(6), 465-469.
302. R.T. Turner, G.L. Evans, et al. (1993) Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption. J. Bone Miner. Res. 8(3), 359-366.
303. R.T. Turner, G.L. Evans, et al. (1994) Reduced chondroclast differentiation results in increased cancellous bone volume in estrogen-treated growing rats. Endocrinology 134(1), 461-466.
304. R.T. Turner, L.S. Kidder, et al. (1999) Estrogen has rapid tissue-specific effects on rat bone. J. Appl. Physiol. 86(6), 1950-1958.
305. R.T. Turner, E.T. Lifrak, et al. (1990) Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am. J. Physiol. 258(4 Pt 1), E673-e677.
306. R.T. Turner, B.L. Riggs, et al. (1994) Skeletal effects of estrogen. Endocr. Rev. 15(3), 275-300.
307. R.T. Turner, J.J. Vandersteenhoven, et al. (1987) The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J. Bone Miner. Res. 2(2), 115-122.
308. R.T. Turner, G.K. Wakley, et al. (1990) Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J. Orthop. Res. 8(4), 612-617.
309. R.T. Turner, G.K. Wakley, et al. (1987) Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J. Bone Miner. Res. 2(5), 449-456.
310. R.T. Turner, G.K. Wakley, et al. (1988) Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122(3), 1146-1150.
311. Y. Umayahara, R. Kawamori, et al. (1994) Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269(23), 16433-16442.
312. L. Vandenput, L.G. Ederveen, et al. (2001) Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem. Biophys. Res. Commun. 285(1), 70-76.
313. B. Vandewalle and J. Lefebvre (1989) Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol. Cell Endocrinol. 61(2), 239-246.
314. A. Venn, F. Bruinsma, et al. (2004) Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 364(9444), 1513-1518.
315. H.J. Verhaar, C.A. Damen, et al. (1994) A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 15(3), 307-311.
316. O. Vidal, L.G. Kindblom, et al. (1999) Expression and localization of estrogen receptor-beta in murine and human bone. J. Bone Miner. Res. 14(6), 923-929.
317. O. Vidal, M.K. Lindberg, et al. (2000) Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. U. S. A. 97(10), 5474-5479.
318. K. Waller, J. Reim, et al. (1996) Bone mass and subtle abnormalities in ovulatory function in healthy women. J. Clin. Endocrinol. Metab. 81(2), 663-668.
319. Q. Wang, J.H. Yu, et al. (2006) Temporal expression of estrogen receptor alpha in rat bone marrow mesenchymal stem cells. Biochem. Biophys. Res. Commun. 347(1), 117-123.
320. T. Watanabe, S. Inoue, et al. (1997) Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta. Biochem. Biophys. Res. Commun. 236(1), 140-145.
321. C.K. Watts, M.G. Parker, et al. (1989) Stable transfection of the oestrogen receptor gene into a human osteosarcoma cell line. J. Steroid Biochem. 34(1–6), 483-490.
322. C.M. Weaver and J.M. Cheong (2005) Soy isoflavones and bone health: The relationship is still unclear. J. Nutr. 135(5), 1243-1247.
323. L.L. Wei, M.W. Leach, et al. (1993) Evidence for progesterone receptors in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 195(2), 525-532.
324. K.C. Westerlind, K.J. Gibson, et al. (1998) Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J. Bone Miner. Res. 13(6), 1023-1031.
325. K.C. Westerlind, G.K. Wakley, et al. (1993) Estrogen does not increase bone formation in growing rats. Endocrinology 133(6), 2924-2934.
326. K.C. Westerlind, T.J. Wronski, et al. (1997) Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. U. S. A. 94(8), 4199-4204.
327. S.H. Windahl, R. Galien, et al. (2006) Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J. Clin. Invest. 116(9), 2500-2509.
328. S.H. Windahl, M. Norgard, et al. (2000) Cellular distribution of estrogen receptor beta in neonatal rat bone. Bone 26(2), 117-121.
329. S.H. Windahl, O. Vidal, et al. (1999) Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 104(7), 895-901.
330. T.J. Wronski, M. Cintron, et al. (1988) Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif. Tissue Int. 43(3), 179-183.
331. T.J. Wronski, M. Cintron, et al. (1988) Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123(2), 681-686.
332. T.J. Wronski, L.M. Dann, et al. (1989) Time course of vertebral osteopenia in ovariectomized rats. Bone 10(4), 295-301.
333. T.J. Wronski, C.C. Walsh, et al. (1986) Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 7(2), 119-123.
334. T.J. Wronski, C.F. Yen, et al. (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132(2), 823-831.
335. H. Xie, S.Y. Tang, et al. (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int. 80(3), 201-210.
336. K. Yamada, K. Nozawa-Inoue, et al. (2003) Expression of estrogen receptor alpha (ER alpha) in the rat temporomandibular joint. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol. 274(2), 934-941.
337. Y. Yamaguchi (2007) Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 14(2), 175-181.
338. N.N. Yang, H.U. Bryant, et al. (1996) Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137(5), 2075-2084.
339. J.K. Yeh, M.M. Chen, et al. (1997) Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy. Am. J. Physiol. 273(4 Pt 1), E734-e742.
340. K. Yoshitake, K. Yokota, et al. (1999) Effects of 16 weeks of treatment with tibolone on bone mass and bone mechanical and histomorphometric indices in mature ovariectomized rats with established osteopenia on a low-calcium diet. Bone 25(3), 311-319.
341. G. Zaman, H.L. Jessop, et al. (2006) Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. J. Bone Miner. Res. 21(8), 1297-1306.
342. S. Zecchi-Orlandini, L. Formigli, et al. (1999) 17beta-estradiol induces apoptosis in the preosteoclastic FLG 29.1 cell line. Biochem. Biophys. Res. Commun. 255(3), 680-685.
343. B.T. Zhu and H. Conney (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 58(11), 2269-2277.
344. C.F. Zizola, M.E. Balana, et al. (2002) Changes in IGF-I receptor and IGF-I mRNA during differentiation of 3T3-L1 preadipocytes. Biochimie 84(10), 975-980.